Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot2 - STU 1 ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example EvidenceVariable: Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)

version: 5; Last updated: 2025-09-14 18:30:51+0000

Profile: VariableDefinition

EvidenceVariableHandlingDetail: Evidence variable handling not specified

url: https://fevir.net/resources/EvidenceVariable/267227

identifier: FEvIR Object Identifier/267227, FEvIR Linking Identifier/NCT03421379-secondaryOutcome-0

name: Pharmacodynamics_PD_Change_From_Baseline_in_Maximal_Blood_Glucose_BGmax_of_Glucagon_Nasal_Powder_and_Glucagon_Hydrochloride_Intramuscular_IM_NCT03421379

title: Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379)

citeAs:

Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379) [Database Entry: FHIR EvidenceVariable Resource]. Contributors: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267227. Revised 2025-09-14. Available at: https://fevir.net/resources/EvidenceVariable/267227. Computable resource at: https://fevir.net/resources/EvidenceVariable/267227#json.

status: Active

author: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter:

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

PD assessment measured the change from Baseline in maximal blood glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride intramuscular (IM).

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

Definitions

-Reference
*Group: membership = conceptual

handling: extension

Generated Narrative: Group #variable-definition

membership: Conceptual

characteristic

code: defined by CodeableConcept

value: Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM)

exclude: false

Timings

-Text
*Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration